Zolgensma IV injection, from Novartis Pharma, contains Onasemnogen Abeparvobec (YJ code: 4900404X1020, per patient). This gene therapy is indicated for pediatric patients less than two years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the SMN1 gene, providing a functional copy of the gene.
Zolgensma IV injection
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →